Overview of Disarval

Property	Description
Active Ingredients	Amlodipine, Valsartan
Form	Oral Tablet (Fixed-Dose Combination)
Pharmacological Class	Antihypertensive (CCB and ARB)
Common Use	Management of high blood pressure
Origin	Synthetic

Disarval: Classification and Core Identity

Disarval is a prescription-only pharmaceutical entity classified as an antihypertensive agent, specifically designed for the management of high blood pressure (essential hypertension). This medication is a fixed-dose combination product, which delivers two distinct, synthetic active compounds in a single oral dosage form. This strategic formulation is often referred to as dual therapy, a method for providing a comprehensive approach to blood pressure control in adult patients whose pressure is not adequately managed by a single agent. The fixed nature of the tablet simplifies administration compared to taking two separate medications.

What is the Composition of Disarval?

The medicine is composed of the two active ingredients: Amlodipine and Valsartan. Amlodipine is a Dihydropyridine Calcium Channel Blocker (CCB), and Valsartan is an Angiotensin II Receptor Blocker (ARB). This specific pairing differentiates it from similar formulations that might combine an ARB with a diuretic. The rationale behind combining these two distinct classes focuses on achieving broader therapeutic efficacy against complex or persistent hypertension.

What is the General Therapeutic Purpose of the Dual-Action Agent?

The general purpose of Disarval is to achieve a sustained and effective reduction of elevated blood pressure. This desired outcome stems from its dual-action mechanism: Amlodipine facilitates vasodilatory effects by promoting muscle relaxation in arterial walls, while Valsartan provides hormonal antagonism by blocking the effects of Angiotensin II. This complementary approach helps to ease the resistance of blood flow, leading to a clinically relevant lowering of pressure throughout the circulatory system. By simultaneously targeting two distinct pathways that regulate vasoconstriction and fluid balance, Disarval helps ease the workload on the cardiovascular system.

Regulatory References

What side effects are possible with Disarval?

Possible side effects and safety information

Regulatory documents classify the potential adverse reactions of Disarval based on their frequency of occurrence and the organ system affected. The most frequently documented reactions are typically classified as Common, affecting 1 to 10 users in 100, and often include headache, dizziness, fatigue, and peripheral edema (swelling), with the latter being a known dose-dependent effect of the Amlodipine component . Reactions are organized into System-Organ Classes (SOCs), such as Nervous System disorders and Vascular disorders.

Serious Adverse Reactions and Safety Constraints

Official labeling explicitly documents Serious Adverse Reactions that require clinical attention, including Angioedema (severe swelling of the face, lips, tongue, or throat) and the potential for Acute Renal Failure or Hypersensitivity Reactions. The safety profile also outlines critical Safety Constraints for specific patient populations, defining the scope of acceptable use.

Population/Condition	Regulatory Safety Note
Pregnancy	Contraindicated during the second and third trimesters due to risk of fetal injury and death

. | | Severe Hepatic Impairment | Avoid use due to increased exposure to both active ingredients. | | Hypotension Risk | Risk of symptomatic hypotension is noted, especially at treatment initiation in volume-depleted patients. |

Disarval is also contraindicated in patients with a prior history of angioedema related to an ACE inhibitor or ARB. The official safety information structures the understanding of risks by separating expected effects from serious, rare events, establishing clear constraints on its use as defined by government regulatory authorities.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Disarval is officially documented to result from the combined effects of its components, focusing on excessive influence over the cardiovascular system. The primary clinical manifestations listed in regulatory information include pronounced systemic hypotension and excessive peripheral vasodilatation. Dizziness is also cited as a potential sign, and the amlodipine component may result in reflex tachycardia.

Due to the severity of these effects, official labeling warns of marked and potentially prolonged systemic hypotension, which carries a documented risk of escalating to shock with fatal outcome. Consequently, any suspected overexposure or resulting symptomatic effects necessitates seeking immediate professional medical attention.

Since no specific antidote is known for this combination, management is defined as symptomatic and supportive. The regulatory documents describe specific procedural measures for managing critical blood pressure drops. These mandated measures include placing the patient in the supine position and administering an intravenous infusion of normal saline, if required, to stabilize the patient’s condition. Due to its high protein-binding, hemodialysis is unlikely to be an effective measure for removing amlodipine from the body.

Therapeutic Uses of Disarval

Disarval is a medication used to help manage serious conditions affecting the heart and blood vessels. Its primary therapeutic purpose is the treatment of hypertension, or high blood pressure, to assist in controlling blood pressure levels. The reduction of blood pressure is a key factor in mitigating the potential for major cardiovascular events.

Additional clinical uses include supporting the treatment of heart failure (NYHA class II-IV) to help reduce the necessity for hospitalization related to the condition. Furthermore, in certain clinically stable patients who have experienced a myocardial infarction (heart attack) and have residual left ventricular dysfunction, Disarval is indicated to help lessen the risk of adverse cardiovascular outcomes. The overall benefit is derived from managing these chronic conditions, which assists in supporting long-term heart health. The specific indications for use are established for these therapeutic areas.

Quick Fact: Relief for High Blood Pressure

Disarval is utilized to help achieve and sustain control over elevated blood pressure, a primary risk factor in cardiovascular health.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Disarval

Official regulatory documents define the eligible patient population and formal contraindications for use of Disarval.

Eligibility Scope	Status and Applicable Populations
Allowed	Adults with hypertension, as determined by a healthcare provider.
Not Recommended	Patients with severe renal impairment (e.g., creatinine clearance leq 30 mL/min); pediatric patients under 6 years; and breastfeeding/nursing mothers.
Contraindicated	Patients with known hypersensitivity to amlodipine, valsartan, or related dihydropyridines.
Contraindicated	Pregnancy, particularly during the second and third trimesters, due to risk of harm to the fetus.
Contraindicated	Patients with severe hepatic impairment, anuria (absence of urine production), biliary cirrhosis, or cholestasis.
Contraindicated	Concomitant use with aliskiren in patients with diabetes or moderate-to-severe renal impairment.
Restrictions	Caution is required in patients with specific severe electrolyte imbalances or conditions like aortic stenosis, mitral stenosis, or hypertrophic obstructive cardiomyopathy.

This eligibility structure is based strictly on the absolute exclusions and restrictions documented in official government-issued drug labeling. Use in the pediatric population over 6 years old is not formally established and requires special consideration.

What should I know about interactions with other medicines?

Disarval is a fixed-dose combination containing amlodipine and valsartan. Its interaction profile is based on the known interactions of these two active ingredients.

Medications Requiring Caution or Monitoring

Interacting Product Category	Key Concern/Condition for Use
Lithium	Not recommended; close monitoring of lithium levels is required due to risk of increased lithium toxicity.
Potassium-Raising Medicines	Increased risk of high potassium levels (hyperkalaemia). Includes potassium supplements, potassium-sparing diuretics, and salt substitutes containing potassium. Requires frequent monitoring of blood potassium levels.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Increased risk of worsening kidney function, especially in elderly or dehydrated patients, and possible reduction of Disarval's blood pressure-lowering effect.
CYP3A4 Inhibitors (e.g., ketoconazole, diltiazem)	May increase amlodipine levels in the blood, potentially leading to lower blood pressure and increased side effects.
CYP3A4 Inducers (e.g., rifampicin, St. John’s Wort)	May decrease amlodipine levels, potentially reducing the effectiveness of Disarval.
Other Antihypertensive Agents	Increased risk of low blood pressure (hypotension) due to additive effects.

Inform your doctor or pharmacist of all prescription and non-prescription medicines, herbal remedies, and supplements you are taking to manage potential interactions effectively.

Mechanism of Action

Disarval, which corresponds to the compound Valsartan, functions primarily as a selective angiotensin II receptor antagonist (ARB). Its molecular target is the angiotensin II type 1 ( AT1) receptor, which is expressed on the surface of numerous cells, including those in vascular smooth muscle and the adrenal gland.

Disarval competitively binds to the AT1 receptor, preventing the endogenous pressor hormone angiotensin II from activating the receptor. This blockade of the AT1 receptor disrupts the intracellular signaling cascade typically triggered by angiotensin II binding, which involves G-protein coupled receptor (GPCR) activation. The inhibition of this signaling pathway leads to a decrease in AT1-mediated effects, notably the reduction of vasoconstriction in peripheral arteries and the suppression of aldosterone synthesis and release from the adrenal cortex. The systemic physiological consequence of this dual effect is the modulation of vascular resistance and fluid-electrolyte balance, ultimately leading to a reduction in systemic arterial pressure.

Dosage and Administration Information

How Disarval Is Used in Clinical Practice

Disarval is a fixed-dose combination prescribed exclusively for oral use in the management of hypertension. The administration protocol is designed for consistency and long-term use, generally involving a once-daily dosing schedule at a consistent time each day.

Titration, or adjustment of the dose, is performed gradually in response to the patient's condition. Increases in the strength of the tablet typically occur after a minimum of one to two weeks following the prior change, which allows the healthcare provider to assess the full therapeutic effect before moving toward the maximum daily dose of 10 mg amlodipine and 320 mg valsartan.

Official Administration Conditions

Feature	Official Labeled Instruction
Route of Administration	Oral only, using the film-coated tablet.
Timing Relative to Meals	May be taken with or without food.
Preparation	Tablets must be swallowed whole with water. No crushing or alteration is permitted.
Frequency	Strictly once daily (qDay).

Population-Specific Use Parameters

Specific parameters are observed for certain patient populations:

Geriatric Patients (ge 65 years): When initiating treatment, a lower starting dose of the amlodipine component is typically utilized, though the 2.5 mg amlodipine strength is not available in the combination tablet.
Hepatic Impairment (Mild/Moderate): The maximum recommended dose for the valsartan component is 80 mg to account for reduced clearance.
Renal Impairment (Mild/Moderate): No initial dose adjustment is required for patients with a glomerular filtration rate (GFR) ge 30 mL/min/1.73 m^2.

This protocol describes the administrative framework for the medication.

Recent Clinical Evidence

Research evidence / Overview of Studies for Disarval

The following outlines the available research evidence for Disarval and its components, describing the studies conducted and the patterns observed, while maintaining strict neutrality about therapeutic claims.

Evidence for use in Essential Hypertension

Research has explored the fixed-dose combination in controlled clinical trials used in research exploring how physiological metrics evolved over short time intervals. These studies were primarily randomized, short-term comparisons that monitored physiological strain or stress by measuring changes in blood pressure (Systolic and Diastolic Blood Pressure). The study populations consisted of adults with essential hypertension, including those previously studied on monotherapy.

The findings describe patterns observed in the studies, where data indicated differences in measured blood pressure when compared to when the individual components were studied alone. This research provides insight into short-term changes and how blood pressure evolved in the observed populations during the trial period. Studies monitored how patients fared in achieving specific, pre-set blood pressure goals.

Evidence for use in High-Risk Cardiovascular Conditions (Valsartan Component)

It is important to understand that the research supporting the use of the drug in high-risk cardiovascular conditions is primarily based on large, long-term studies where only the Valsartan component was observed. These studies explored conditions marked by functional limitations, such as heart failure or changes in heart function following a heart attack.

Research Supporting Post-Myocardial Infarction Use

The Valsartan component was evaluated in large trials involving patients in a stable condition shortly after they had experienced a heart attack and showed reduced function in the left side of the heart. Studies monitored physiological strain or stress and tracked long-term survival and hospitalization events over defined, long time intervals.

Research Supporting Heart Failure Management

The Valsartan component was also studied for chronic conditions involving periods of heightened symptoms, specifically heart failure classified as NYHA Class II to IV. Research was conducted in observational settings evaluating outcomes reflecting daily functioning and tracked long-term survival and hospitalization endpoints. Research provides context on how this component was observed in patients already receiving standard heart failure treatments.

What is Still Uncertain About Disarval

This section outlines the research limitation frames that currently apply to the evidence base. Certainty remains low regarding the impact of the fixed-dose combination on major cardiovascular events because the trials used in research exploring short-term symptom changes often involved follow-up durations that were limited. Data for certain groups remain insufficient, and research is ongoing to better understand its use in the broader population. Findings describe group patterns, not personal outcomes, and studies help show what has been observed so far.

Frequently Asked Questions (FAQ)

Common questions about Disarval (FAQ)

Q: How quickly do official documents say Disarval might start working?

Regulatory documents indicate that the majority of the blood pressure-lowering effect is achieved within approximately two weeks after starting the medicine or after a change in dose. This time frame allows healthcare professionals to accurately assess the full therapeutic impact of the medication.

Q: What happens if a dose of Disarval is missed?

Official patient information advises that if a dose is missed, it should be taken as soon as remembered. However, if it is nearly time for the next scheduled dose, the recommendation is to skip the missed one. Official guidance indicates that the dose should not be doubled to compensate for a missed dose.

Q: Is it typical for patients to experience [mild side effect example] when starting Disarval?

Lightheadedness and dizziness are noted as possible effects, particularly when first starting treatment or when the dose is increased. This is related to the medicine's primary purpose of lowering blood pressure. If this occurs, official materials indicate that this should be noted by a healthcare professional.

Q: How long is the typical duration of use for Disarval?

The medicine is officially indicated for the treatment of essential hypertension, or high blood pressure. Since high blood pressure is typically a chronic condition, treatment with Disarval generally requires long-term, ongoing management to maintain reduced blood pressure.

Q: What does the patient leaflet say about discontinuing Disarval?

Official guidance stresses that patients should not stop taking the medicine suddenly without consulting their healthcare professional first. Abruptly stopping therapy may cause an increase in blood pressure, a condition that should be managed by a healthcare provider.

Q: What is the official information regarding alcohol consumption while using Disarval?

Warnings in official drug interaction databases describe a moderate interaction between the medication and alcohol. Consuming alcohol may have an additive effect in lowering blood pressure, which could potentially increase the risk of symptoms like dizziness and fainting.

Q: What are the official restrictions for taking Disarval while breastfeeding?

Regulatory information advises that breastfeeding is generally not recommended while taking this medication. This restriction is based on the lack of data confirming whether the active ingredients are passed into human breast milk.

Q: Does Disarval cause drowsiness or make it difficult to focus?

Regulatory documents list dizziness and fatigue as common adverse effects. While the specific terms 'drowsiness' or 'difficulty focusing' are not typically noted among the most common reactions, these related effects may influence a person's concentration or energy level.

Q: Are there any common reasons Disarval is stopped by patients?

Clinical trial data provides insight into the most common reasons patients stopped taking the drug due to side effects. The most frequently reported adverse reactions that led to discontinuation were peripheral edema (swelling in the hands or feet) and vertigo (dizziness).

Q: Is Disarval known to interact with herbal supplements?

The official labeling advises caution with various supplements. Specifically, it identifies St. John’s Wort as a potential concern because it may reduce the amount of the amlodipine component in the blood. Official guidance generally recommends informing a healthcare professional about all supplements being used.

Q: Can Disarval affect the results of common laboratory tests?

Yes, regulatory information indicates that the use of this medicine requires ongoing monitoring of certain lab values. This monitoring focuses primarily on the patient's serum potassium levels and the evaluation of their kidney function.

Q: Are there published studies showing the effects of Disarval in older adults?

Official prescribing information includes a dedicated section discussing the use of the drug in older adults. Regulatory documents note that exposure to the valsartan component is often higher and its half-life is longer in elderly patients, which informs dose considerations.

Q: What types of food or drink are mentioned in official guidance regarding Disarval?

Official guidance includes a specific warning about the use of salt substitutes containing potassium. This caution is necessary because the valsartan component in the medicine can increase the risk of hyperkalaemia (high potassium levels), which can be exacerbated by these substitutes.

Q: Is Disarval suitable for people with a history of heart issues?

Official warnings require careful consideration for use in patients who have certain existing heart conditions, such as severe aortic or mitral stenosis or a history of recent myocardial infarction (heart attack).

Q: Is Disarval used as a first-line treatment for its indication?

The drug is indicated for two main purposes according to regulatory documents. It is used to lower blood pressure in patients not adequately controlled on monotherapy (a single drug) OR it can be used as the initial therapy for patients who are likely to require multiple medicines to reach their blood pressure goals.

Q: What are the typical age limits for prescribing Disarval?

Regulatory information indicates the medicine is intended for use in adults with hypertension. There is a specific precaution against use in pediatric patients under 6 years of age noted in official documents.

Q: What is the relationship between Disarval and laboratory monitoring?

The official labeling notes that the medicine requires regular laboratory monitoring. The primary focus of this monitoring is on the patient's serum potassium levels and the evaluation of kidney function.

Q: Is Disarval available over the counter in any country?

The product is officially classified as a prescription-only medication in regulatory documents across major jurisdictions. This means it is only dispensed by a pharmacy under the direct authorization of a healthcare professional.

Q: Are there any warnings about taking Disarval with large amounts of vitamins?

Warnings in official drug interaction databases advise caution regarding the co-administration of multivitamins with minerals. This is because the combination may potentially reduce the effectiveness of the amlodipine component of the drug.

Q: Is Disarval intended to cure or manage the condition?

The drug is indicated for the treatment (or management) of hypertension. It is designed to help control and lower elevated blood pressure, but it does not provide a cure for the underlying chronic condition.

How should Disarval be stored and disposed of?

How to Store and Dispose of Disarval? (Amlodipine/Valsartan)

Official regulatory labeling dictates specific conditions for storing and disposing of this medicine to maintain its stability and safety profile.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Environment	Protect from excessive moisture; do not refrigerate or freeze.
Safety	Keep the tablets out of the reach and sight of children.

Disposal Instructions

Unused or expired Disarval tablets should be disposed of according to federal and local guidelines. The preferred method is using an authorized drug take-back program. If a take-back option is unavailable, the tablets must be mixed with an unappealing substance, such as dirt or used coffee grounds, sealed in a container, and placed in the household trash. The product is not recommended for disposal by flushing down the toilet.

Disarval